今日要闻！Meta再掀裁员潮：扎克伯格目标300多名副总裁

Meta再掀裁员潮：扎克伯格目标300多名副总裁

北京讯 继2023年的大规模裁员之后，Meta平台（META.US）似乎并未停止其精简管理层的步伐。据知情人士透露，Meta CEO马克·扎克伯格近日再次指示公司进行裁员，并将目标瞄准了公司臃肿的副总裁群体。

消息称，扎克伯格希望将Meta的副总裁数量从去年的300人左右减少到250人左右，这意味着约有50名副总裁将被解雇。这批被裁减的副总裁主要来自Meta的各个业务部门，包括Reality Labs、Facebook、Instagram和WhatsApp等。

扎克伯格此举被认为是Meta为应对经济困境和提高效率所采取的措施。2023年，Meta的股价遭遇重挫，市值蒸发了超过一半。与此同时，Meta的营收增速也明显放缓。为了重振业绩，扎克伯格一直在努力提高公司的运营效率。

去年，Meta曾宣布将2023年定为“效率年”，并采取了一系列措施来精简业务，包括裁员、冻结招聘和削减成本等。这些措施在一定程度上帮助Meta控制了成本，但也导致了员工士气的下降。

有分析人士认为，Meta此次裁员副总裁可能会进一步加剧员工的担忧情绪。不过，也有分析人士认为，裁员是Meta转型过程中必要的举措，只有通过提高效率才能重振公司业绩。

目前，Meta尚未正式公布此次裁员计划。但从目前的迹象来看，Meta的管理层调整仍在进行中，未来可能还会有更多高管被波及。

以下是对该新闻的一些扩充和分析：

• 扎克伯格此次裁员副总裁的举动可能引发外界对Meta管理层能力的质疑。此前，Meta就曾因决策失误和管理不善而受到诟病。
• 裁员可能会进一步加剧Meta员工的焦虑情绪，并导致人才流失。
• 扎克伯格需要拿出更有效的措施来重振Meta业绩，否则他可能会面临更大的压力。

新的标题：

• Meta再掀裁员潮：扎克伯格高压瘦身 副总裁成首要目标

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.